# Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.

> **NCT05168215** · — · UNKNOWN · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Scleroderma
- Digital Ulcer
- Autoimmune Diseases
- Diffuse Cutaneous Systemic Sclerosis
- Reynold Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05168215
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168215, "Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05168215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*